Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate sodium, quantity: 2.742 mg (equivalent: methotrexate, qty 2.5 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose - antineoplastic chemotherapy: treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and section 4.4). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultations. rheumatoid arthritis chemotherapy: (see warnings box and section 4.4). management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Philippines - English - FDA (Food And Drug Administration)

the university of the phils manila (upm) - national integrated research program on medicinal plants (nirpromp) - vitex negundo l. (lagundi) leaf - tablet - 300mg

Philippines - English - FDA (Food And Drug Administration)

university of the philippines manila (upm) national integrated research program on medicinal plants (nirpromp) - vitex negundo l. (lagundi leaf) - tablet - 600mg

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) - tablet, coated - 25 mg - hypertension (see boxed warning). hypersensitivity to reserpine; mental depression or history of mental depression (especially with suicidal tendencies); active peptic ulcer, ulcerative colitis; patients receiving electroconvulsive therapy. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease. anuria; hypersensitivity to this or other sulfonamide-derived drugs.

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - voriconazole - film-coated tablet - voriconazole 50 mg - antimycotics for systemic use

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - voriconazole - film-coated tablet - voriconazole 200 mg - antimycotics for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - ambrisentan - film-coated tablet - 10 milligram(s) - other antihypertensives; ambrisentan

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - ambrisentan - film-coated tablet - 5 milligram(s) - other antihypertensives; ambrisentan

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat